Orphazyme changes Chairman in search of capital
![Foto: Stine Bidstrup](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6074541.ece/ALTERNATES/schema-16_9/27095152%2520-%252007_02_2012%2520-%2520BIDSTRUP%2520STINE.jpg)
The Chairman of biotech company Orphazyme for the past four years, Martin Bonde, has been replaced. According to Martin Bonde, who is also CEO of EpiTherapeutics and president of the industry association Dansk Biotek, Orphazyme has reached a point when a change at the top makes good sense.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
EpiTherapeutics brings in Merck’s oncology deputy
For abonnenter
Biotech Chairman: You pay for the network
For abonnenter
Biotech CEO: Front runners drive the sector
For abonnenter